The in vitro OC anti-CRC activity was compared with a wide range of targeted therapies, including the first- and third-generation EGFR inhibitors gefitinib and osimertinib, respectively, and the experimental standard SMYD2 and c-MET inhibitors BAY-598 and SU11274, respectively (Table 1). This evidence concerns the gene SMYD2 and colorectal carcinoma.